Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides oral solid formulations for ARVs, anti-diabetic, cardiovascular, and PPIs. In addition, the company offers contract development and manufacturing organizational services; and biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products. Further, the company develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceuticals field. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.

Revenue projections:

Revenue projections for LAURUSLABS
Revenue projections for LAURUSLABS

Laurus Labs Limited's revenue projections indicate a decrease from last year's performance, which could lead to investor caution. A fall in revenue is likely to negatively impact the company's profitability, causing concern for shareholders who may view this as a signal of declining financial health.

Financial Ratios:

currentRatio 0.000000
forwardPE 54.629692
debtToEquity 44.831000
earningsGrowth 1.719000
revenueGrowth 0.257000
grossMargins 0.570230
operatingMargins 0.202210
trailingEps 15.590000
forwardEps 18.652860

Laurus Labs Limited's forward PE ratio is too high, which may hinder future price growth and increase the risk of a price correction. Investors should carefully evaluate this metric along with other key financial indicators to get a full picture of the stock's potential.
With positive earnings and revenue growth, LAURUSLABS is on a path to expand its business. This strong financial performance suggests the company will continue to grow, as increasing profits and revenue highlight a healthy outlook.
LAURUSLABS's positive gross and operating margins reflect strong profitability and operational efficiency. These metrics indicate the company's ability to control costs while maintaining healthy revenue, contributing to its solid financial performance.
LAURUSLABS's forward EPS is higher than its trailing EPS, which signals that the company is expected to achieve greater profitability this financial year. This suggests improved earnings performance, indicating a positive outlook for LAURUSLABS's financial growth.

Price projections:

Price projections for LAURUSLABS
Price projections for LAURUSLABS

LAURUSLABS's price projections have gradually increased over time, indicating that analysts are becoming more optimistic about the company's prospects. This suggests confidence in LAURUSLABS's ability to achieve future growth.

Recommendation changes over time:

Recommendations trend for LAURUSLABS
Recommendations trend for LAURUSLABS


The sell bias toward LAURUSLABS from analysts suggests caution, but investors are encouraged to consult a variety of market indicators before making decisions. This broader perspective will help mitigate risks and provide a clearer understanding of LAURUSLABS's potential in the current market.